PET-imaging of Two Vartumabs in Patients With Solid Tumors

VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS). Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues. VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these a

Trial Details

NCT ID
NCT06645808
Phase
EARLY_PHASE1
Sponsor
Var2 Pharmaceuticals
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • 89Zr-DFO-N-Suc-F8scFv
  • 89Zr-DFO-N-Suc-C9scFv
  • PET/CT scan
Locations (sample)
  • Groningen, Provincie Groningen, Netherlands|53.21917,6.56667

Key Eligibility Criteria

  • Willing to adhere to the prohibitions and restrictions specified in this protocol.
  • Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study …
  • Patients aged ≥ 18 years at moment of signing informed consent form.
  • Life expectancy of \> 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →